Reported 2 months ago
Eli Lilly has raised its annual sales forecast by $3 billion due to increased demand for its weight-loss drug Zepbound, which surpassed $1 billion in sales for the first time. The company reports strong growth in both Zepbound and Mounjaro, attributing their success to stable pricing and high consumer demand. Shares surged nearly 12% as Lilly plans to enhance its manufacturing capabilities in response to the unprecedented market demand.
Source: YAHOO